Supplementary Figures 1-8, Tables 1-9 from Functional Viability Profiles of Breast Cancer

Rachel Brough(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Jessica Frankum(Institute of Cancer Research), Maria Antonietta Cerone(Cancer Research Horizons), Rumana Rafiq(Institute of Cancer Research), Ilirjana Bajrami(Institute of Cancer Research), Spiros Linardopoulos(Abzena (United Kingdom)), Amar Ahmad(Cancer Research UK), Ana M. Mendes‐Pereira(Institute of Cancer Research), Rachael Natrajan(Institute of Cancer Research), Teeara Rawjee(Institute of Cancer Research), Nicholas C. Turner(Institute of Cancer Research), Alan Mackay(Institute of Cancer Research), Jorge S. Reis‐Filho(AstraZeneca (France)), Rachel Sharpe(Guy's Hospital), Sara Costa-Cabral(Institute of Cancer Research), David Sims(Marine Biological Association of the United Kingdom), Daniel Wetterskog(CRUK Lung Cancer Centre of Excellence), Christopher J. Lord(Institute of Cancer Research), Konstantine J. Dedes(Institute of Cancer Research), Maryou B. Lambros(Institute of Cancer Research), Kai‐Keen Shiu(University College London Hospitals NHS Foundation Trust)
Unknown
April 3, 2023
10.1158/2159-8290.22528829
Cited by 0

Related Papers

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k